Posts tagged ‘commercial development’
It is hard to imagine what going blind must be like, so any new technology that restores some sense of vision and shape perception is of tremendous value to those affected.
Pieter Droppert who has worked on ophthalmology clinical trials, comments on the recent news that aptly named, Second Sight, has obtained a CE mark for their Argus II Retinal Prosthesis System; the first device of its kind to be approved.
Obtaining a CE (Conformité Européenne) mark indicates that a medical device has met an appropriate quality and safety standard. The result is that it can be freely marketed and sold throughout the 30 member countries of the European Economic Area (EEA) without any further regulatory approval being necessary. It is a major landmark for any medical device company, equivalent to obtaining FDA approval in the United States.
Further commentary on how Second Sight’s “artificial retina” works and what this “bionic eye” means for those who are blind can be found on Biotech Strategy Blog.
Innovation is one of the themes that Pieter Droppert writes about on the Biotech Strategy Blog. As management consultants we are interested in new product development strategy, and how to bring novel drugs and devices to market.
In his latest blog post, Pieter discusses an article published on the Harvard Business Review blog that suggests we may be able to learn from how innovation is taking place in emerging markets.
Emerging markets, in particular the BRIC countries: Brazil, Russia, India & China, are driving the growth of the world’s leading pharmaceutical companies. It’s interesting to think that the developed world may be able to learn from emerging economies.
Today on Pharma Strategy Blog, Sally Church comments on the sheer volume of data associated with modern science, a topic considered by Science magazine in their February 11, 2011 issue.
What makes this close to our heart at Icarus Consultants, is that what we do for a living as a marketing strategy company focusing on the life sciences, pharmaceutical and biotechnology industries, is process a lot of data. Anybody can provide you with a data dump of all the posters or presentations from a scientific meeting, but what does this data mean, what do the key opinion leaders think and what are the strategic implications that come out of it?
In the internet era, the amount of data available to us is increasing, but we are faced by more demands on our time. That’s why people often hire us, not to do what they cannot do themselves, but what they don’t have the time to do. It takes time to process data and generate analysis and insight.
More perspective on this topic can be found on Pharma Strategy Blog.
Published by Sally Church on Pharma Strategy Blog
Published by Sally Church on Pharma Strategy Blog
Published by Pieter Droppert on Biotech Strategy Blog